Artesunate interacts with Vitamin D receptor to reverse mouse model of sepsis-induced immunosuppression via enhancing autophagy

Shenglan Shang; Jiaqi Wu; Xiaoli Li; Xin Liu; Pan Li; Chunli Zheng; Yonghua Wang; Songqing Liu; Jiang Zheng; Hong Zhou

For AS treatment, AS (5, 10, and 20 µg/mL) was added with LPS (5 ng/mL) and LPS (100 ng/mL) simultaneously. For autophagy inhibitors treatment, 3-methyladenine (3-MA, 5 mM) (Sigma-Aldrich), bafilomycin A1(Baf, 10 ng/mL) (MedChemExpress, NJ, USA) and LY294002 (Sigma-Aldrich, 10 μM) was added 2 h before the first LPS (5 ng/mL), and also with AS treatment simultaneously. The supernatants and cells were collected at 6 h after the last LPS (100 ng/mL) addition. The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.26.966143 doi: bioRxiv preprint NC-OE. The shRNA targeting mouse VDR (5′-CCTCAAACTCTGATCTGTA-3′), NF-κB p65 (5′-CCCTCAGCACCATCAACTTTG-3′) and the negative control shRNA (5′-TTCTCCGAACGTGTCACGT-3′) were designed, synthesized and inserted into the lentivirus vector (#GV248, GeneChem) by the GeneChem Corporation (Shanghai, China).